Effect of CYP2C19 polymorphism on serum levels of vitamin B12 in patients on long-term omeprazole treatment

Alimentary Pharmacology and Therapeutics

Volumn 13, Issue 4, 1999, Pages 453-458

  Sagar, M ^a   Janczewska, I ^a   Ljungdahl, A ^a   Bertilsson, L ^b   Seensalu, Rein ^a,c  

^a ST GÖRAN S HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; OMEPRAZOLE; STOMACH SECRETION INHIBITOR;

ADULT; AGED; ARTICLE; DNA POLYMORPHISM; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PEPTIC ULCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; VITAMIN BLOOD LEVEL;

ANTI-ULCER AGENTS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; ESOPHAGITIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; PEPTIC ULCER; POLYMORPHISM, GENETIC; VITAMIN B 12;

EID: 0032917214     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1999.00490.x     Document Type: Article

References (41)

1. Wilde MI, McTavish D. Omeprazole. An update of its pharmacology and therapeutic use in acid related disorders. Drugs 1994; 48: 91-132.
2. Hetzel DJ, Dent J, Reed WD, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988; 95: 903-12.
3. Lamberts R, Creutzfeldt W, Struber HG, Brunner G, Solcia E. Long-term omeprazole therapy in peptic ulcer disease: Gastrin, endocrine cell growth, and gastritis. Gastroenterology 1993: 104: 1356-70.
4. Regärdh CG. Pharmacokinetics and metabolism of omeprazole in man. Scand J Gastroenterol 1986; 21(Suppl. 118): 99-104.
5. Cederberg C, Andersson T, Skanberg I. Omeprazole: Pharmacokinetics and metabolism in man. Scand J Gastroenterol 1989; 24 (Suppl. 166): 33-40.
6. Andersson T, Regardh CG, Lou YC, Zhang Y, Dahl ML, Bertilsson L. Polymorphichydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 1992; 2: 32-7.
7. Sohn DR, Kobayashi K, Lee KH, Shin SG, Ishizaki T. Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4-hydroxylation recruited from Oriental population. J Pharmacol Exp Ther 1992; 262: 1195-1202.
8. Nakamura K, Goto F, Ray WA, et al. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian population. Clin Pharmacol Ther 1985; 38: 402-8.
9. Bertilsson L, Lou Y-Q, Du Y-L, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 1992; 51: 188-97.
10. Bertilsson L, Kalow W. Why are diazepam metabolism and polymorphic S-mephenytoin hydroxylation associated with each other in white and Korean populations but not in Chinese population? Clin Pharmacol Ther 1993; 53: 608-10.
11. De Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994; 269: 15 419-22.
12. Chang M, Dahl ML, Tybring G, Götharson E, Bertilsson L. Use of omeprazole as probe drug for CYP2C19 phenotype in Swedish Caucasians: Comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 1995; 5: 358-63.
13. de Morais SM, Wilkinson GR, Blaisdell J, Nukamura K, Meyer UA, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994; 46: 594-8.
14. Sagar M, Seensalu R, Tybring G, Dahl ML, Bertilsson L. CYP2C19 genotype and phenotype determined with omeprazole in patients with acid related disorders with and without H. pylori infection. Scand J Gastroenterol 1998; 33: 1034-38.
15. Allen RII. Cobalamin (vitamin B12) absorption and malabsorption. Viewpoint Dig Dis. 1982; 14: 17-20.
16. Herzlich B, Herbert V. Rapid collection of human intrinsic factor uncontaminated with cobalphin (r binder). Am J Gastroenterol 1986; 81: 678-80.
17. Herzlich B, Herbert V. The role of the pancreas in cobalamin (vitamin B12) absorption. Am J Gastroenterol 1984; 79: 489-93.
18. Festen HP. Intrinsic factor secretion and cobalamin absorption. Physiology and pathophysiology in the gastrointestinal tract. Scand J Gastroenterol 1991; 26(Suppl. 188): 1-7.
19. Neal G. B12 binding proteins. Gut 1990; 31: 59-63.
20. Streeter AM, Duraiappali B, Boyle R, O'Neill BJ, Phelis MT. Malabsorption of vitamin B12 after vagotomy. Am J Surg. 1974; 128: 340-3.
21. 57-vitamin B12 in patients with hypochlorhydria and achlorohydria and after gastric resection. Gastroenterology. 1973; 64: 913-19.
22. King CE, Leibach J, Toskes PP. Clinically significant vitamin B12 deficiency secondary to malabsorption of protein-bound vitamin B12. Dig Dis Sci 1979; 24: 397-402.
23. Steinberg WM, King CE, Toskes PP. Malabsorption of protein-bound cobalamin but not unbound cobalamin during cimetidine administration. Dig Dis Sci 1980; 25: 188-92.
24. Streeter AM, Goulston KJ, Bathur FA, Hilmer RS, Crane GG, Pheils MT. Cimetidine and malabsorption of cobalamin. Dig Dis Sci 1982; 27: 13-16.
25. Belaiche J, Cattan D, Zittoun J, Marquet J, Yvart J. Effects of ranitidine on cobalamin absorption. Dig Dis Sci 1983; 28: 667-8 (Letter).
26. Salom IL, Silvis SE, Doscherholmen A. Effect of cimetidine on the absorption of vitamin B12. Stand J Gastroenterol 1982; 17: 129-31.
27. Lanzon-Miller S, Pounder RE, Hamilton MR, et al. Twenty-four hour intragastric acidity and plasma gastrin concentration before and during treatment with either ranitidine or omeprazole. Aliment Pharmacol Ther 1987; 1: 239-51.
28. Festen HPM, Tuynman HARE, den Hollander W, Meuwissen SGM. Repeated high oral doses of omeprazole do not affect intrinsic factor secretion: Proof of a selective mode of action. Aliment Pharmacol Ther 1989; 3: 375-9.
29. Kittang E, Aaland E, Schønby H. Effect of omeprazole on the secretion of intrinsic factor, gastric acid and pepsin in man. Gut 1985; 26: 591-8.
30. Herbert V, Drivas G, Manusselis B, Eng J, Schwartz E. Are colon bacteria a major source of cobalaminanalogues in human tissues? 24-hr human stool contains only about 5 micrograms of apparent analogue (and 200 micrograms of folate). Trans Assoc Am Physicians 1984; 97: 161-71.
31. Koop H. Review article: Metabolic consequences of long-term inhibition of acid secretion by omeprazole. Aliment Pharmacol Ther 1992; 6: 399-406.
32. Lee GR. Megaloblastic and nonmegaloblastic macrocytic anemias. In: Wintrobe MM, Lee GR, Bithell TC, Foester J, Athens JW, Lukens JN, eds. Wintrobe's Clinlcal Hematology, 9th Edn. Philadelphia: Lea & Febiger 1993; 740: 754-90.
33. Sagar M, Tybring G, Dahl M-L, Bertilsson L, Seensalu R, The effect of omeprazole on intragastric pH and gastrin levels is determined by the CYP2C19 polymorphism more than by H. pylori infection in patients with acid related disease. Gastroenterology 1998; 114(4): A1122(Abstract).
34. Furuta T, Ohashik K, Takaahima M, Hanai H, Kubota T, Ishizaki T et al. CYP2C19 genotype status and effect of omeprazole. Gastroenterology 1998; 114(4): A0521 (Abstract).
35. Saltzman JR, Golner BB, et al. Effect of hypochlorhydria due to omeprazole treatment or atrophic gastritis on protein bound vitamin 12 absorption. J Am Coll Nutr 1994; 13: 584-91.
36. Marcuard SP, Albernaz L, Khazanie PG. Omeprazole therapy cause malabsorption of cyanocobalamin (vitamin B12). Ann Intern Med 1994; 120: 211-215.
37. Festen H, Tertoolen J. Malabsorption of protein-bound but not unbound cobalamin during treatment with omeprazole. Gastroenterology 1988; 94: A125(Abstract).
38. Kittang E, Aadland E, Schjonsby H, Rohss K. The effect of omeprazole on gastric acidity and the absorption of liver cobalamins. Scand J Gastroenterol 1978; 22: 156-60.
39. Koop H, Bachem MG. Serum iron, ferritin and vitamin B12 during prolonged omeprazole therapy. J Clin Gastroenterol 1992; 14: 288-92.
40. Termanini B, Gibril F, Sutliff VE, Yu F, Venzon D, Jensen RT. Effect of long-term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome. Am J Med 1998; 104: 422-30.
41. Bellou A, Aimone-Gastin I, De Korwin JD et al. Cobalamin deficiency with megaloblastic anaemia in one patient under long-term omeprazole therapy. J Intern Med 1996; 24: 161-4.